LAVA THERAP. B.V. EO-12
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more
LAVA THERAP. B.V. EO-12 (4PKB) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LAVA THERAP. B.V. EO-12 (4PKB) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LAVA THERAP. B.V. EO-12 - Net Assets Trend (None–None)
This chart illustrates how LAVA THERAP. B.V. EO-12's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LAVA THERAP. B.V. EO-12 (None–None)
The table below shows the annual net assets of LAVA THERAP. B.V. EO-12 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LAVA THERAP. B.V. EO-12's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LAVA THERAP. B.V. EO-12 Competitors by Market Cap
The table below lists competitors of LAVA THERAP. B.V. EO-12 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Road King Infrastructure Limited
PINK:RKGXF
|
$25.97 Million |
|
Hyunwoo Industrial Co. LTD
KQ:092300
|
$25.97 Million |
|
Mondi Turkey Oluklui Mukavva Kagit ve Ambalaj Sanayi A.S.
IS:MNDTR
|
$25.97 Million |
|
LPP SA
PINK:LPPSY
|
$25.97 Million |
|
GASCOGNE S.A.INH. EO 250
F:G5O
|
$25.96 Million |
|
Vietnam Manufacturing and Export Processing (Holdings) Limited
TW:9110
|
$25.94 Million |
|
Capinfo Company Limited
F:CF90
|
$25.92 Million |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
$25.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LAVA THERAP. B.V. EO-12's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LAVA THERAP. B.V. EO-12's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LAVA THERAP. B.V. EO-12 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LAVA THERAP. B.V. EO-12's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LAVA THERAP. B.V. EO-12 (4PKB) | €- | N/A | N/A | $25.96 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |